Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Genes Chromosomes Cancer. 2019 Aug;58(8):541-550. doi: 10.1002/gcc.22739. Epub 2019 Feb 11.
Vascular malformations are part of overgrowth syndromes characterized by somatic mosaic mutations or rarely by germline mutations. Due to their similarities and diversity, clinicopathological classification can be challenging. A comprehensive targeted Next Generation Sequencing screen using Unique Molecular Identifiers with a technical sensitivity of 1% mutant alleles was performed for frequently mutated positions in ≥21 genes on 319 formalin-fixed paraffin-embedded samples. In 132 out of 319 cases pathogenic mosaic mutations were detected affecting genes previously linked to vascular malformations e.g. PIK3CA (n=80), TEK (TIE2) (n=11), AKT1 (n=1), GNAQ (n=7), GNA11 (n=4), IDH1 (n=3), KRAS (n=9), and NRAS (n=1). Six cases harbored a combination of mutations in PIK3CA and in GNA11 (n=2), GNAQ (n=2), or IDH1 (n=2). Aberrations in PTEN and RASA1 with a variant allele frequency approaching 50% suggestive of germline origin were identified in six out of 102 cases tested; four contained a potential second hit at a lower allele frequency. Ninety-one of the total 142 pathogenic mutations were present at a variant allele frequency <10% illustrating the importance of sensitive molecular analysis. Clinicopathological characteristics showed a broad spectrum and overlap when correlated with molecular data. Sensitive screening of recurrently mutated genes in vascular malformations may help to confirm the diagnosis and reveals potential therapeutic options with a significant contribution of PIK3CA/mTOR and RAS-MAPK pathway mutations. The co-existence of two activating pathogenic mutations in parallel pathways illustrates potential treatment challenges and underlines the importance of multigene testing. Detected germline mutations have major clinical impact.
血管畸形是一种过度生长综合征的一部分,其特征是体细胞镶嵌突变,或很少由种系突变引起。由于它们的相似性和多样性,临床病理分类可能具有挑战性。对 319 例福尔马林固定石蜡包埋样本进行了使用具有 1%突变等位基因技术灵敏度的独特分子标识符的靶向下一代测序综合筛选,这些样本中≥21 个基因的常见突变位置。在 319 例病例中的 132 例中,检测到了致病性镶嵌突变,这些突变影响了先前与血管畸形相关的基因,例如 PIK3CA(n=80)、TEK(TIE2)(n=11)、AKT1(n=1)、GNAQ(n=7)、GNA11(n=4)、IDH1(n=3)、KRAS(n=9)和 NRAS(n=1)。有 6 例病例同时存在 PIK3CA 和 GNA11(n=2)、GNAQ(n=2)或 IDH1(n=2)的突变组合。在 102 例经测试的病例中,有 6 例存在接近 50%的种系来源变体等位基因频率的 PTEN 和 RASA1 异常,其中 4 例的等位基因频率较低,存在潜在的第二个打击。在总共 142 个致病性突变中,有 91 个的变异等位基因频率<10%,这说明了敏感分子分析的重要性。当与分子数据相关联时,临床病理特征表现出广泛的重叠。在血管畸形中对反复突变基因进行敏感筛选可能有助于确认诊断,并揭示具有 PIK3CA/mTOR 和 RAS-MAPK 途径突变的潜在治疗选择。平行途径中两种激活致病性突变的共存说明了潜在的治疗挑战,并强调了多基因检测的重要性。检测到的种系突变具有重大的临床影响。